

**Tetrahedron Letters**

Volume 31, Issue 11, 1990, Pages 1517-1520

doi:10.1016/0040-4039(90)80004-6 [Cite or link using doi](#)

Copyright © 1990 Published by Elsevier Science Ltd. All rights reserved.

Comparison of three methods for the synthesis of carborane carboxylic acid esters**This Document**

- [Abstract](#)
- [Abstract + References](#)
- [PDF \(262 K\)](#)

Actions

- [E-mail Article](#)

Stephen B. Kahl

Department of Pharmaceutical Chemistry University of California, San Francisco San Francisco, CA 94143-0446, USA

Received 18 December 1989. Available online 15 March 2001.

Abstract

Three procedures for the esterification of polyhedral carborane carboxylic acids with long chain unsaturated fatty alcohols are compared with regard to rate of reaction, ease of isolation and over-all yield. The optimum procedure is based on room temperature reaction of the acid chloride and alcohol in the presence of 4-dimethylaminopyridine in CH_2Cl_2 .

Graphical Abstract

Esterification of 1,2-dicarbaclosododecaboranyl monocarboxylic acid with ten unsaturated fatty alcohols, as exemplified here with palmitoleyl alcohol, occurs most efficiently *via* reaction of the acid chloride and alcohol in the presence of p-dimethylamino pyridine.

**Tetrahedron Letters**

Volume 31, Issue 11, 1990, Pages 1517-1520

This Document

- [Abstract](#)
- [Abstract + References](#)
- [PDF \(262 K\)](#)

Actions

- [E-mail Article](#)



Send [feedback](#) to ScienceDirect

Software and compilation © 2004 ScienceDirect. All rights reserved.

ScienceDirect® is a registered trademark of Elsevier B.V.

Your use of this service is governed by [Terms and Conditions](#). Please review our [Privacy Policy](#) for details on how we protect information that you supply.


SCIENCE @ DIRECT

Register or Login: user name Password: Go Athens Logon

[Home](#) [Journals](#) [Abstract Databases](#) [Books](#) [Reference Works](#) [My Profile](#) [Alerts](#)

Help ? [WELCOME GUEST USER](#) [Info](#)

Biochemical and Biophysical Research Communications

Volume 262, Issue 1 , 19 August 1999, Pages 275-284

doi:10.1006/bbrc.1999.1105 Cite or link using doi
 Copyright © 1999 Academic Press. All rights reserved.

This Document

 Abstract Abstract + References PDF (126 K)

Actions

 E-mail Article**Regular Article**

Unsaturated Long-Chain *N*-Acyl-vanillyl-amides (N-AVAMs): Vanilloid Receptor Ligands That Inhibit Anandamide-Facilitated Transport and Bind to CB1 Cannabinoid Receptors^{*1}

Dominique Melck^{a, 1}, Tiziana Bisogno^{a, 1}, Luciano De Petrocellis^b, Huai-hu Chuang^c, David Julius^c, Maurizio Bifulco^d and Vincenzo Di Marzo^{a, 2}

Istituto per la Chimica di Molecole di Interesse Biologico³

^b Istituto di Cibernetica, Consiglio Nazionale delle Ricerche, Via Toiano 6, 80072, Arco Felice, Napoli, Italy

^c Department of Cellular and Molecular Pharmacology, University of California, San Francisco, California, 94143-0450

^d C.E.O.S., CNR, and Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università di Napoli Federico II, 80131, Napoli, Italy

Received 29 June 1999. Available online 2 April 2002.

Abstract

We investigated the effect of changing the length and degree of unsaturation of the fatty acyl chain of *N*-(3-methoxy-4-hydroxy)-benzyl-*cis*-9-octadecenoamide (olvanil), a ligand of vanilloid receptors, on its capability to: (i) inhibit anandamide-facilitated transport into cells and enzymatic hydrolysis, (ii) bind to CB1 and CB2 cannabinoid receptors, and (iii) activate the VR1 vanilloid receptor. Potent inhibition of [¹⁴C]anandamide accumulation into cells was achieved with C20:4 n-6, C18:3 n-6 and n-3, and C18:2 n-6 *N*-acyl-vanillyl-amides (N-AVAMs). The saturated analogues and Δ^9 -*trans*-olvanil were inactive. Activity in CB1 binding assays increased when increasing the number of *cis*-double bonds in a n-6 fatty acyl chain and, in saturated N-AVAMs, was not greatly sensitive to decreasing the

chain length. The C₂₀:4 n-6 analogue (arvanil) was a potent inhibitor of anandamide accumulation ($IC_{50} = 3.6 \mu M$) and was 4-fold more potent than anandamide on CB1 receptors ($K_i = 0.25\text{--}0.52 \mu M$), whereas the C₁₈:3 n-3 N-AVAM was more selective than arvanil for the uptake ($IC_{50} = 8.0 \mu M$) vs CB1 receptors ($K_i = 3.4 \mu M$). None of the compounds efficiently inhibited [¹⁴C]anandamide hydrolysis or bound to CB2 receptors. All N-AVAMs activated the cation currents coupled to VR1 receptors overexpressed in *Xenopus* oocytes. In a simple, intact cell model of both vanilloid- and anandamide-like activity, i.e., the inhibition of human breast cancer cell (HBCC) proliferation, arvanil was shown to behave as a "hybrid" activator of cannabinoid and vanilloid receptors.

Author Keywords: cannabinoid; endocannabinoid; capsaicin; analgesics; breast cancer cells; carrier

*¹ Abbreviations used: N-AVAM, *N*-acyl-vanillyl-amide; VR1, vanilloid receptor type 1; RBL, rat basophilic leukemia; CB1, CB2, cannabinoid receptor type 1 and 2; TRP, transient receptor potential; TRPL, transient receptor potential-like; RTX, resiniferatoxin; FAAH, fatty acid amide hydroxylase; AM404, *N*-(4-hydroxyphenyl)-arachidonylamide; anandamide, *N*-arachidonoyl-ethanolamine; olvanil, *N*-(3-methoxy-4-hydroxy)-benzyl-*cis*-9-octadecenoamide; palvanil, *N*-(3-methoxy-4-hydroxy)-benzyl-hexadecanamide; arvanil, *N*-(3-methoxy-4-hydroxy)-benzyl-arachidonylamide; pseudocapsaicin, *N*-(3-methoxy-4-hydroxy)-benzyl-nonanamide; HBCC, human breast cancer cell

¹ These authors contributed equally to this work.

² Address correspondence and reprint requests to this author. Fax: +39-081-8041770. E-mail: VDM@TRINC.ICMIB.NA.CNR.IT.

³ Affiliated with the National Institute for the Chemistry of Biological Systems, Consiglio Nazionale delle Ricerche.

Biochemical and Biophysical Research Communications

Volume 262, Issue 1, 19 August 1999, Pages 275-284

This Document

• **Abstract**

- [Abstract + References](#)
- [PDF \(126 K\)](#)

Actions

- [E-mail Article](#)

*Send [feedback](#) to ScienceDirect

Software and compilation © 2004 ScienceDirect. All rights reserved.

ScienceDirect® is a registered trademark of Elsevier B.V.

Your use of this service is governed by [Terms and Conditions](#). Please review our [Privacy Policy](#) for details on how we protect information that you supply.